Changes in resistance among coliform bacteraemia associated with a primary care antimicrobial stewardship intervention: a population-based interrupted time series study by Hernandez Santiago, Virginia et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Changes in resistance among coliform bacteraemia associated
with a primary care antimicrobial stewardship intervention: a
population-based interrupted time series study
Citation for published version:
Hernandez Santiago, V, Davey, PG, Nathwani, D, Marwick, CA & Guthrie, B 2019, 'Changes in resistance
among coliform bacteraemia associated with a primary care antimicrobial stewardship intervention: a
population-based interrupted time series study', PLOS Medicine.
https://doi.org/10.1371/journal.pmed.1002825
Digital Object Identifier (DOI):
10.1371/journal.pmed.1002825
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
PLOS Medicine
Publisher Rights Statement:
This is an open access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source
are credited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 12. Sep. 2019
RESEARCH ARTICLE
Changes in resistance among coliform
bacteraemia associated with a primary care
antimicrobial stewardship intervention: A
population-based interrupted time series
study
Virginia Hernandez-Santiago1, Peter G. Davey2, Dilip Nathwani3, Charis A. MarwickID2*,
Bruce GuthrieID4
1 Division of Population and Behavioural Sciences, School of Medicine, University of St Andrews, St
Andrews, United Kingdom, 2 Division of Population Health and Genomics, School of Medicine, University of
Dundee, Dundee, United Kingdom, 3 Academic Health Sciences Partnership in Tayside, Ninewells Hospital
and Medical School, Dundee, United Kingdom, 4 Usher Institute of Population Health Sciences and
Informatics, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United
Kingdom
* c.z.marwick@dundee.ac.uk
Abstract
Background
Primary care antimicrobial stewardship interventions can improve antimicrobial prescribing,
but there is less evidence that they reduce rates of resistant infection. This study examined
changes in broad-spectrum antimicrobial prescribing in the community and resistance in
people admitted to hospital with community-associated coliform bacteraemia associated
with a primary care stewardship intervention.
Methods and findings
Segmented regression analysis of data on all patients registered with a general practitioner
in the National Health Service (NHS) Tayside region in the east of Scotland, UK, from 1 Jan-
uary 2005 to 31 December 2015 was performed, examining associations between a primary
care antimicrobial stewardship intervention in 2009 and primary care prescribing of fluoro-
quinolones, cephalosporins, and co-amoxiclav and resistance to the same three antimicro-
bials/classes among community-associated coliform bacteraemia. Prescribing outcomes
were the rate per 1,000 population prescribed each antimicrobial/class per quarter. Resis-
tance outcomes were proportion of community-associated (first 2 days of hospital admis-
sion) coliform (Escherichia coli, Proteus spp., or Klebsiella spp.) bacteraemia among adult
(18+ years) patients resistant to each antimicrobial/class. 11.4% of 3,442,205 oral antimi-
crobial prescriptions dispensed in primary care over the study period were for targeted anti-
microbials. There were large, statistically significant reductions in prescribing at 1 year
postintervention that were larger by 3 years postintervention when the relative reduction
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was −68.8% (95% CI −76.3 to −62.1) and the absolute reduction −6.3 (−7.6 to −5.2) people
exposed per 1,000 population per quarter for fluoroquinolones; relative −74.0% (−80.3 to
−67.9) and absolute reduction −6.1 (−7.2 to −5.2) for cephalosporins; and relative −62.3%
(−66.9 to −58.1) and absolute reduction −6.8 (−7.7 to −6.0) for co-amoxiclav, all compared
to their prior trends. There were 2,143 eligible bacteraemia episodes involving 2,004
patients over the study period (mean age 73.7 [SD 14.8] years; 51.4% women). There was
no increase in community-associated coliform bacteraemia admissions associated with
reduced community broad-spectrum antimicrobial use. Resistance to targeted antimicrobi-
als reduced by 3.5 years postintervention compared to prior trends, but this was not statisti-
cally significant for co-amoxiclav. Relative and absolute changes were −34.7% (95% CI
−52.3 to −10.6) and −63.5 (−131.8 to −12.8) resistant bacteraemia per 1,000 bacteraemia
per quarter for fluoroquinolones; −48.3% (−62.7 to −32.3) and −153.1 (−255.7 to −77.0) for
cephalosporins; and −17.8% (−47.1 to 20.8) and −63.6 (−206.4 to 42.4) for co-amoxiclav,
respectively. Overall, there was reversal of a previously rising rate of fluoroquinolone resis-
tance and flattening of previously rising rates of cephalosporin and co-amoxiclav resistance.
The limitations of this study include that associations are not definitive evidence of causation
and that potential effects of underlying secular trends in the postintervention period and/or
of other interventions occurring simultaneously cannot be definitively excluded.
Conclusions
In this population-based study in Scotland, compared to prior trends, there were very large
reductions in community broad-spectrum antimicrobial use associated with the stewardship
intervention. In contrast, changes in resistance among coliform bacteraemia were more
modest. Prevention of resistance through judicious use of new antimicrobials may be more
effective than trying to reverse resistance that has become established.
Author summary
Why was this study done?
• Antimicrobial resistance is an increasing global public health threat, and antimicrobial
use in humans is a key driver of resistance development. The majority of antimicrobial
prescribing occurs in the community, and there is evidence that a significant proportion
of such prescribing is unnecessary.
• Antimicrobial stewardship interventions aim to improve antimicrobial use. There is
increasing evidence that they are effective in influencing rates of the targeted prescribing
in both primary and secondary care, but there is much less reliable evidence on their
effect on resistance.
• A primary care antimicrobial stewardship intervention in the Tayside region of Scot-
land, UK, in 2009 was intended to reduce broad-spectrum antimicrobial use in the com-
munity. We used this opportunity to examine changes associated with the intervention
in prescribing of three individual targeted antimicrobials and changes in resistance to
Antimicrobial resistance associated with primary care stewardship
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these antimicrobials among community-associated bloodstream infections using rou-
tinely collated population data.
What did the researchers do and find?
• We conducted segmented regression analyses of interrupted time series data on com-
munity prescribing of fluoroquinolones, cephalosporins, and co-amoxiclav between
2005 and 2012 and on resistance to the same antimicrobials among common gram-neg-
ative bloodstream infections (E. coli, Klebsiella spp., and Proteus spp.) identified on
admission to hospital. We modelled immediate changes in rates and in trends associated
with the stewardship intervention and estimated changes in prescribing (compared to
predicted rates if the intervention had not occurred) 1 and 3 years later, and in resis-
tance 1.5 and 3.5 years later (incorporating a prespecified expected 6-month delay
between changes in prescribing and changes in resistance).
• We found large and sustained reductions in prescribing of all three antimicrobials asso-
ciated with implementation of the stewardship intervention.
• We found reductions in coliform bacteraemia resistance rates associated with the inter-
vention that were significant for fluoroquinolones and cephalosporins by 3.5 years but
not for co-amoxiclav. The reductions in resistance took much longer than reductions in
prescribing to become evident, and relative reductions were more modest. The overall
pattern was of flattening rather than reversal of previously rising resistance rates.
What do these findings mean?
• Antimicrobial stewardship interventions in primary care have a role in containing anti-
microbial resistance in serious infections.
• Very large changes in prescribing were associated with much smaller changes in resis-
tance. Preventing development of resistance through careful use of new antimicrobials
may be more effective than attempting to reverse established resistance.
Introduction
Increasing antimicrobial resistance (AMR) is a major global public health threat [1,2]. An esti-
mated 2 million people have resistant infections in the United States annually, with associated
longer hospital stays and more costly antimicrobial treatment; an estimated 25,000 associated
deaths occur annually in the European Union, and 23,000 in the US [3,4]. Coliforms, princi-
pally E. coli, are the commonest cause of bacteraemia, with incidence rates rising internation-
ally [5,6]. Resistant E. coli bacteraemia is associated with higher mortality and poorer health
outcomes, at least partly due to increased risk of initial antimicrobial therapy being inappro-
priate [7–11].
Higher antimicrobial use is associated with increased resistance at both population [12] and
individual [13] levels. Up to one-third of ambulatory care antimicrobial use is estimated to be
inappropriate [14], with widespread inappropriate use of broad-spectrum antimicrobials [15].
Antimicrobial use is therefore considered the most modifiable cause of AMR [12,16].
Antimicrobial resistance associated with primary care stewardship
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Antimicrobial stewardship interventions have been widely implemented [17], with demon-
strated reductions in targeted prescribing, but the effect on AMR is as yet unclear because few
studies of antimicrobial stewardship interventions robustly examine the effects on resistance
[18].
The most recent systematic review and meta-analysis of the effect of stewardship on subse-
quent AMR included 32 studies and reported that stewardship interventions in hospitals were
associated with reductions in colonisation and infection with multi-drug–resistant gram-nega-
tive bacteria [19]. However, only two (6%) of the included studies were judged to be high-qual-
ity by the review authors, not least because almost all included studies had an uncontrolled
before–after design, which is unreliable (particularly in this context, in which interventions are
often triggered by outbreaks, which usually remit without any intervention, and include
changes to infection control as well as prescribing). In the most recent systematic reviews of
antimicrobial stewardship interventions selecting for higher-quality studies, effects on AMR
were examined by only 15 (7%) included studies of hospital-based stewardship interventions,
and only four (10%) included studies of community-based interventions [18,20]. All four com-
munity-based studies examined Streptococcus pneumoniae resistance, with only one showing
declining macrolide resistance following reductions in community macrolide use [21].
Although restricting the use of a new antimicrobial is expected to minimise the development
of resistance, it therefore remains uncertain whether reductions in existing antimicrobial use
will translate into lower resistance, particularly in the community, where most antimicrobials
are prescribed [21,22].
A primary care stewardship intervention implemented across the National Health Service
(NHS) Tayside region of Scotland, UK, in 2009 was associated with large (>50%) reductions
in total aggregate primary care prescribing of four broad-spectrum antimicrobials in primary
care (fluoroquinolones, cephalosporins, co-amoxiclav, and clindamycin; targeted primarily
because all are associated with Clostridium difficile infection) [23]. In the years since the inter-
vention, serious gram-negative (particularly coliform) infection and antimicrobial resistance
have been recognised as increasingly important problems, with three of the antimicrobials tar-
geted in the intervention commonly used in treatment of coliform infections (coliform bacte-
ria are intrinsically resistant to clindamycin). The aim of this study was to separately examine
changes in prescribing of fluoroquinolones, cephalosporins, and co-amoxiclav over a longer
period and to examine whether there were any associated changes in resistance to these anti-
microbials in patients admitted to hospital with community-associated coliform bacteraemia.
Methods
Study context and antimicrobial stewardship intervention
In the Tayside region of Scotland, all healthcare is provided by the NHS with the exception of
some less complicated elective surgery. All residents are registered with a single general prac-
tice providing primary medical care, and the regional NHS microbiology laboratory carries
out all culture and sensitivity testing. Primarily in response to concerns about rising rates of C.
difficile infection, in 2009, NHS Tayside implemented a multifaceted antimicrobial steward-
ship intervention to reduce the use of broad-spectrum antimicrobials in primary care. The
intervention consisted of prescriber education, guideline development and dissemination,
change of the primary care antimicrobial guideline format and content, feedback of compara-
tive prescribing data at practice level with target setting in relation to formulary adherence,
and small financial incentives to participate in improvement work (approximately £390/€441/
US$497 for an average-sized practice with approximately 5,500 registered patients).
Antimicrobial resistance associated with primary care stewardship
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002825 June 7, 2019 4 / 19
The educational component of the intervention comprised both written guidance and phar-
macist-facilitated educational outreach (academic detailing) to practices. Written educational
material included revised antimicrobial guidance and a special edition of the Tayside Pre-
scriber newsletter focused on raising awareness about C. difficile infection, including avoiding
broad-spectrum antimicrobials associated with it. Educational outreach included face-to-face
dissemination of the new antimicrobial prescribing guidance to practices and general practi-
tioners and discussion of the prescribing targets set for primary care. In parallel, practices’
antimicrobial prescribing was audited at both practice and individual prescriber level, with
feedback of prescribing rates compared to other practices in the region. Feedback data
informed target setting for each practice with the aim of increasing formulary adherence,
involving practices agreeing to reduce fluoroquinolone use in general and for respiratory
infections in particular and to reduce antimicrobial use without a documented indication.
Practices also agreed to implement a practice policy for dealing with inappropriate or tele-
phone requests for antimicrobials.
We have previously reported that the intervention was associated with a rapid, large, and
sustained decrease in an aggregate measure of total targeted broad-spectrum antimicrobial
prescribing (fluoroquinolones, cephalosporins, co-amoxiclav, and clindamycin) in all age
groups [23].
Data
The University of Dundee Health Informatics Centre (HIC) provided data from 1 January
2005 to 31 December 2015 on all blood culture isolates in the region (total including negative
results = 157,229, total gram-negative bacteraemia = 4,701), community-dispensed antimicro-
bials (total 3,442,205 prescriptions), patient demography (mean population per study calendar
quarter = 424,014), hospital admissions, and mortality. Linkage between data sets at individual
patient level was done using the NHS Scotland unique patient identifier (the Community
Health Index [CHI] number). The CHI number is used to identify patients during all NHS
Scotland healthcare episodes and is consistent across all data sets. Details of the data sets and
the cleaning and linkage processes are provided as supporting information (S1 Text).
Protocol, ethics, and reporting
This observational study was conducted as part of VHS’s doctoral research and did not have a
published protocol or signed, dated analysis plan. However, all the primary analyses reported
in the main paper were specified prior to examining the outcome data, with the sensitivity
analyses designed post hoc informed by examination of the time trends on request of the statis-
tical reviewer.
HIC Standard Operational Procedures (SOPs) have been approved by both the NHS East of
Scotland Research Ethics Committee and the relevant Caldicott Guardians (who have legal
responsibility for approving use of unconsented NHS patient data). Ethics committee review
of individual studies is not required provided that HIC SOPs are followed, including that all
data analysis is carried out using anonymised data held in the ISO27001 and NHS Scotland
accredited HIC Safe Haven.
The study is reported in accordance with the REporting of studies Conducted using Obser-
vational Routinely collected health Data (RECORD) statement (S1 RECORD Checklist) [24].
Study population
The population for the prescribing analysis included the whole population registered with a
general practitioner in NHS Tayside from 1 January 2005 to 31 March 2012. For the resistance
Antimicrobial resistance associated with primary care stewardship
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analysis, patients were included if they were aged 18+ years and had a hospital admission with
community-associated coliform bacteraemia from 1 January 2005 to 31 December 2015. Coli-
form bacteraemia was defined as isolation of any of E. coli, Klebsiella spp., or Proteus spp. in a
blood culture specimen. Community-associated was defined as an isolate from a blood culture
taken on days 0, 1, or 2 of a hospital admission in patients with no previous hospital admission
in the 30 days prior to index admission date. Only the first eligible isolate per patient per calen-
dar quarter was included.
Outcomes
We examined changes in prescribing for each of the three targeted broad-spectrum antimicro-
bials that are used in gram-negative infection (fluoroquinolones, cephalopsorins, and co-
amoxiclav), measured as the rate of patients per 1,000 population exposed to each antimicro-
bial in primary care in each calendar quarter. We then examined changes in resistance to these
three antimicrobials/classes in community-associated coliform bacteraemia isolates, measured
as the quarterly rate of resistance per 1,000 eligible isolates. Resistance was defined as in vitro
resistance reported by the Tayside Microbiology laboratory, which used Vitek systems (Vitek
until 2007, then Vitek 2 subsequently) and Clinical and Laboratory Standards Institute (CLSI)-
recommended minimum inhibitory concentrations (MICs) during the study period. We clas-
sified isolates in which the MIC indicated intermediate susceptibility as resistant to that anti-
microbial. Prescribing outcomes were measured quarterly from the first quarter of 2005 to the
first quarter of 2012, inclusive, and resistance outcomes were measured quarterly from the first
quarter of 2005 to the fourth quarter of 2015, inclusive.
Statistical analysis
Segmented regression analysis of interrupted time series data plotted quarterly was used to
examine changes in both prescribing and resistance associated with implementation of the
antimicrobial stewardship intervention. Time series analysis is generally acknowledged to be a
robust quasiexperimental method for analysing the effect of interventions that have not been
or cannot be randomised. It allows the statistical assessment of how an intervention is associ-
ated with change in an outcome of interest both immediately and over time [25]. A time series
is repeated observations (aggregate measures at each time point, for example, proportions or
means) of a particular outcome over time, which is then divided (interrupted) into time peri-
ods before and after an intervention. Segmented regression analysis evaluates both changes in
level (i.e., any step change) immediately after the intervention and changes in slope in the post-
intervention period compared to the preintervention period, which serves as the control. Seg-
mented regression controls for the effect of secular time trends, avoiding bias commonly
present in uncontrolled before-and-after comparison of mean rates.
The stewardship intervention was implemented at the start of the second quarter of 2009,
and for the prescribing analysis, this was chosen to be the first time point after the interven-
tion, giving 17 time points before the intervention and 12 time points in the postintervention
segment, as prescribing data from 2005 to 2012 were included in the model. Constraining the
postintervention time period in this way reduced the risks that assumptions of linearity will be
violated and that other stewardship interventions will influence the outcome but includes suf-
ficient time points to evaluate intervention effects, including their sustainability. For resistance
analysis purposes, we a priori assumed that there would be a 6-month lag between intervention
implementation and any associated change in resistance, based on evidence that individual
exposure to antimicrobials is associated with subsequent increased resistance to those antimi-
crobials for up to 6 months [26–29]. The segmented regression model for resistance therefore
Antimicrobial resistance associated with primary care stewardship
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assumed an interruption at the fourth quarter of 2009 (rather than the second quarter) and
included data to the end of 2015, giving 19 preinterruption and 25 postinterruption time
points. Models estimated the baseline level and trend in prescribing and resistance rates before
the interruption and any step change or change in trend following the interruption.
We fitted an autoregressive model to analyse the changes in both prescribing and resistance.
The core model fitted was as follows [25]:
Yt ¼ b0 þ b1 � timet þ b2 � interruptionþ b3 � time after interruptiont þ et;
where Yt is the outcome (for example, the rate per 1,000 coliform bacteraemia with resistance
to a specified antimicrobial) at time t; time is a continuous variable, indicating the number of
quarters from the start of the study period; interruption is an indicator for time points before
and after the interruption; and time after interruption is a continuous variable, indicating the
number of quarters after the interruption. β0 estimates the baseline level of the outcome at the
start of the study, β1 estimates the baseline trend before the interruption, β2 estimates the
immediate change in level of the outcome after the interruption, and β3 estimates the change
in the trend after the interruption.
For prescribing outcomes, we estimated absolute and relative changes at 1 and 3 years after
the intervention. For resistance, since the model interruption was a priori defined to be 6
months after the start of the antimicrobial stewardship intervention, results are reported as
absolute and relative change at 1.5 and 3.5 years after the stewardship intervention (a 6-month
lag, then 1 and 3 years’ follow-up from the modelled interruption). The absolute change was
calculated as the difference between model estimates of the predicted outcome if prior trends
had continued and the outcome given any intervention effect. The relative change is the abso-
lute change as a proportion of the outcome rate that the model predicted would have occurred
if prior trends had continued. We used the bootstrapping method proposed by Zhang [30],
implementing an adaptation of Zhang’s published SAS macro to calculate the 95% CIs for
both absolute and relative percentage change estimates.
For all models, we examined whether there was significant autocorrelation up to fourth-
order autocorrelation using the Durbin–Watson statistic and visual inspection of autocorrela-
tion and partial autocorrelation plots. Lag terms were fitted as required to adjust for significant
autocorrelation and were included in the models if they were statistically significant and
improved model fit. In a similar way, seasonality was explored and adjusted for in the prescrib-
ing models as required. Model outputs for lag and seasonal terms have no meaningful inter-
pretation in terms of estimating changes associated with the intervention, so they are not
reported.
Because of the shape of the resistance time series (Fig 1, right-hand panels), we conducted
two types of post hoc sensitivity analysis for resistance to each of the three antimicrobials.
First, we modelled the outcome against time without fitting any interruption and compared
model fit using the Akaike Information Criterion (AIC) [31] with the model including the
interruption for each antimicrobial. Next, we excluded the first year’s data from each resistance
time series and refitted the models using data from 1 January 2006 to 31 December 2015 and
compared model outputs and estimated absolute and relative changes with the results of the
prespecified analyses.
Results
A total of 3,442,205 oral antimicrobial prescriptions were dispensed in primary care in Tayside
over the study period. Amoxicillin was by far the most prescribed antimicrobial, representing
30.1% of all antimicrobial prescriptions, followed by tetracyclines (11.8%), trimethoprim
Antimicrobial resistance associated with primary care stewardship
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(11.4%), flucloxacillin (10.1%), and macrolides (9.5%). In total, the three targeted broad-spec-
trum antimicrobials included here accounted for 11.2% of all antimicrobial prescribing.
There were 2,143 eligible bacteraemia episodes from 2,004 patients over the whole period
examined (mean age 73.7 [SD 14.8] years; 51.4% women), increasing from 136 in 2005 to 234
in 2015 (Table 1). There was a significant upwards trend in eligible bacteraemia episodes
Fig 1. Rates of community antimicrobial exposure 2005 to 2012 and rates of resistance in community-associated coliform bacteraemia episodes 2005 to
2015 in Tayside in relation to a primary care antimicrobial stewardship intervention implemented in the second calendar quarter of 2009.
https://doi.org/10.1371/journal.pmed.1002825.g001
Antimicrobial resistance associated with primary care stewardship
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(increasing by 0.2 per 100,000 population per quarter, p = 0.01) prior to the intervention but
no significant change in level or trend associated with the intervention (p = 0.26 and p = 0.53,
respectively) (S1 Fig and S1 Table). Over the whole period, E. coli was isolated in 81.8% of
Table 1. CB episodes per study year in total, by study eligibility, by organism, and by length of stay and mortality for patients with eligible bacteraemia in each
study year.
Year Total
number of
CB isolatesa
Number of patients with
CB on day 0, 1, or 2 of a
hospital admissionb
Number of
eligible
CA-CBc
Number of E.
coli CA-CB (%
of CA-CB)
Number of
Klebsiella CA-CB
(% of CA-CB)
Number of
Proteus CA-CB
(% of CA-CB)
Median length of
stay CA-CBd in
days (IQR)
Number of CA-CB
patients died within
30 dayse (% of
CA-CB)% (95% CI) of all CB % (95% CI)
of all CB
2005 313 190 136 108 (79.4) 17 (12.5) 11 (8.1) 12.8 (11.7 to
14.4)
28 (20.6)
60.7% (55.0 to 66.1) 43.4% (37.9
to 49.1)
2006 293 194 132 100 (75.8) 22 (16.7) 10 (7.6) 16.2 (16.0 to
16.6)
23 (18.6)
66.2% (60.4 to 71.5) 45.1% (39.2
to 50.9)
2007 372 219 149 115 (77.1) 19 (12.7) 15 (10.1) 15.9 (14.1 to
19.2)
23 (15.7)
58.9% (53.7 to 73.9) 40.1% (35.1
to 45.2)
2008 388 235 153 128 (83.7) 14 (9.1) 11 (7.2) 18.1 (16.1 to
22.5)
13 (8.1)
60.6% (55.5 to 65.4) 39.4% (34.6
to 44.5)
2009 490 278 188 158 (84.0) 20 (10.6) 10 (5.3) 17.1 (14.7 to
19.7)
28 (14.9)
56.7% (52.1 to 61.1) 38.4% (34.1
to 42.8)
2010 479 298 203 174 (85.7) 22 (10.8) 7 (3.4) 13.6 (12.1 to
14.6)
37 (18.4)
62.2% (57.7 to 66.5) 42.4% (37.9
to 46.9)
2011 501 323 220 174 (79.1) 35 (15.9) 11 (5.0) 15.9 (13.4 to
18.2)
20 (8.5)
64.5% (60.1 to 68.6) 43.9% (39.5
to 48.4)
2012 509 342 244 193 (79.1) 33 (13.5) 18 (7.4) 16.8 (13.6 to
19.4)
40 (16.3)
67.2% (62.9 to 71.2) 47.9% (43.5
to 52.3)
2013 491 328 231 188 (81.4) 30 (13.0) 13 (5.6) 12.9 (12.3 to
13.2)
38 (16.3)
66.8% (62.4 to 70.9) 47.1% (42.6
to 51.6)
2014 480 352 253 208 (82.2) 34 (13.4) 11 (4.3) 12.4 (11.2 to
14.0)
39 (15.4)
73.3% 9(67.1 to 79.2) 52.1% (47.1
to 57.2)
2015 486 328 234 196 (83.8) 22 (9.4) 16 (6.8) 12.1 (11.4 to
13.4)
28 (11.9)
67.5% (63.1 to 71.6) 48.1% (43.6
to 52.7)
aCB defined as E. coli, Klebsiella spp., or Proteus spp. isolated from blood culture; numbers include isolates from any point in admission and multiple isolates from the
same patient during an admission or in multiple admissions.
bPatients with one or more CB isolates on day 0, 1, or 2 of hospital admission; numbers include multiple admissions per patient per year.
cCA-CB case is defined as CB on day 0, 1, or 2 of admission in a patient who has not been in hospital in the 30 days before the admission and without a previous CA-CB
in the same calendar quarter.
dLength of stay is median length of hospital stay (and IQR) in days of the admission during which the CA-CB blood culture was taken.
e30-day mortality includes all deaths within 30 days of admission, including out of hospital mortality.
Abbreviations: CA-CB, community-associated CB; CB, coliform bacteraemia.
https://doi.org/10.1371/journal.pmed.1002825.t001
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eligible bacteraemia episodes, compared to Klebsiella spp. in 12.0% and Proteus spp. in 6.2%,
with little change in these proportions over time. Mean length of stay fell slightly, and 30-day
mortality did not change during the study period (Table 1). Across the entire time period,
mean resistance rates were 9.0% for fluoroquinolones, 10.6% for cephalosporins, and 22.6%
for co-amoxiclav. The proportions resistant to more than one of the three antimicrobials were
low, with a maximum 12.8% (24 of 188) resistant to any two and 4.9% (10 of 203) resistant to
all three in any study year, in 2009 and 2010, respectively (S2 Table).
Changes in prescribing
Table 2 shows the results of the interrupted time series analysis, and Table 3 reports the esti-
mated changes associated with the intervention. There was significant autocorrelation in the
prescribing time series for co-amoxiclav but not for fluoroquinolones or cephalosporins,
according to the Durbin–Watson statistic and examination of autocorrelation plots. Adding a
seasonal (in which calendar quarters 1 and 4 are winter and 2 and 3 are summer) term to the
co-amoxiclav model improved model fit and accounted for autocorrelation (S3 Table). Consis-
tent with our previous work examining an aggregate measure of broad-spectrum antimicrobial
prescribing [23], there were large decreases in individual targeted antimicrobials used in
gram-negative infection: fluoroquinolones, cephalosporins, and co-amoxiclav (Fig 1, left-hand
panel). There were no significant trends prior to the intervention for any of these antimicrobi-
als. However, following the intervention, there were statistically significant immediate reduc-
tions in prescribing of −3.8 (95% CI −4.7 to −3.0, p< 0.001) per 1,000 population dispensed
per quarter for fluoroquinolones, of −1.2 (−1.9 to −0.5, p = 0.001) for cephalosporins, and of
−1.9 (−2.6 to −1.3, p< 0.001) for co-amoxiclav (Table 2). The intervention was also associated
with significant changes in trend following the intervention with further significant, additional
decreases of −0.2 (95% CI −0.4 to −0.1, p< 0.001), −0.4 (95% CI −0.5 to −0.3, p< 0.001), and
−0.4 (95% CI −0.5 to −0.3, p< 0.001) patients per 1,000 population dispensed per quarter for
fluoroquinolones, cephalosporins, and co-amoxiclav, respectively. Given preintervention
Table 2. Results of interrupted time series analysis of changes in prescribing of targeted antimicrobials associated with the stewardship intervention.
Baseline prescribing (rate
per 1,000 population at
start of time series)a
Baseline trend (increase [+] or
decrease [−] per quarter of rate
per 1,000 population)a
Step change postintervention
(increase [+] or decrease [−] in rate
per 1,000 population)a
Change in trend postintervention
(increase [+] or decrease [−] in rate per
quarter per 1,000 population)a
Fluoroquinolones 7.9 (7.2 to 8.4) +0.04 (−0.01 to 0.1) −3.8 (−4.7 to −3.0) −0.2 (−0.4 to −0.1)
Cephalosporins 9.3 (8.8 to 9.8) −0.04 (−0.09 to 0.006) −1.2 (−1.9 to −0.5) −0.4 (−0.5 to −0.3)
Co-amoxiclavb 11.1 (10.5 to 11.7) −0.01 (-0.05 to 0.03 −1.9 (−2.6 to −1.3) −0.4 (−0.5 to −0.3)
aRate of patients per 1,000 population exposed to each antimicrobial in each quarter.
bA term for ‘season’ (1 for winter months, i.e., October to March, and 2 for summer months) was fitted for co-amoxiclav prescribing to account for seasonality.
https://doi.org/10.1371/journal.pmed.1002825.t002
Table 3. Estimated absolute and relative change, compared to levels predicted by prior trends, in prescribing of targeted antimicrobials at 1 and 3 years after pri-
mary care stewardship intervention.
Absolute change at 1 year
postintervention compared to
predicted (patients exposed per 1,000
population)
Absolute change at 3 years
postintervention compared to
predicted (patients exposed per 1,000
population)
Relative change at 1 year
postintervention compared
to predicted
Relative change at 3 years
postintervention compared
to predicted
Fluoroquinolones −4.7 (−5.5 to −4.0) −6.3 (−7.6 to −5.2) −53.4% (−58.9 to −47.7) −68.8% (−76.3 to −62.1)
Cephalosporins −2.9 (−3.5 to −2.2) −6.1 (−7.2 to −5.2) −33.9% (−39.2 to −28.3) −74.0% (−80.3 to −67.9)
Co-amoxiclav −3.6 (−4.2 to −3.1) −6.8 (−7.7 to −6.0) −32.7% (−36.4 to −28.9) −62.3% (−66.9 to −58.1)
https://doi.org/10.1371/journal.pmed.1002825.t003
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trends, fluoroquinolone prescribing (which was the main target of the intervention) at 1 and 3
years postintervention was estimated to be −53.4% (95% CI −58.9% to −47.7%) and −68.8%
(−76.3% to −62.1%) lower than expected. These equate to absolute reductions of −4.7 (−5.5 to
−4.0) and −6.3 (−7.6 to −5.2) people exposed per 1,000 population per quarter at 1 and 3 years
postintervention, respectively. There were also large and statistically significant relative reduc-
tions in both cephalosporin and co-amoxiclav prescribing at 1 and 3 years postintervention
(Table 3).
Changes in resistance
Table 4 shows the results of the interrupted time series analysis, and Table 5 reports the esti-
mated changes associated with the intervention. There was significant autocorrelation in the
cephalosporin resistance time series but not for fluoroquinolones or co-amoxiclav. Fitting a
lag 4 term improved both model fit according to AIC and the Durbin–Watson statistic,
accounting for autocorrelation (S4 Table). Resistance to all three targeted antimicrobials was
significantly increasing before the intervention (Fig 1, Table 4), but there were no statistically
significant immediate step changes in resistance at the time of the interruption (Table 4). Pre-
intervention, fluoroquinolone resistance was statistically significantly increasing each quarter
by 3.5/1,000 (95% CI 0.5 to 6.4, p = 0.02) bacteraemia episodes (from a baseline rate of 46.5/
1,000) with a subsequent downwards change in trend postintervention of −4.4/1,000/quarter
(−7.9 to −0.9, p = 0.01). Cephalosporin resistance was statistically significantly increasing each
quarter by 8.2/1,000 bacteraemia episodes (3.5 to 12.9, p = 0.001), from baseline 49.9, with a
downwards change in trend postintervention of −7.0/1,000/quarter (−12.3 to −1.8, p = 0.03).
Co-amoxiclav resistance was nonsignificantly increasing each quarter by 4.6/1,000 bacterae-
mia episodes (−1.0 to 10.3, p = 0.11) with a nonsignificant downward change in slope of −3.3/
1,000/quarter (−10.4 to 3.8, p = 0.33).
There was a relative reduction in fluoroquinolone resistance compared to predicted by 1.5
years after the stewardship intervention (−17.2%, 95% CI −38.4 to 0.04) that increased to
−34.7% (−52.3 to −10.6) by 3.5 years. These equate to absolute reductions of −27.2 (−68.8 to
7.9) and −63.5 (−131.8 to −12.8) resistant bacteraemia episodes per 1,000 per quarter by 1.5
and 3.5 years postintervention, respectively (Table 5). The overall pattern was that a rising
trend in resistance was reversed (Fig 1). Statistically significant relative reductions in cephalo-
sporin resistance of −38.2% (95% CI −56.1 to −18.8) compared to predicted were observed by
1.5 years and −48.3% (95% CI −62.7 to −32.3) by 3.5 years after the stewardship intervention.
Table 4. Results of interrupted time series analysis of changes in AMR to targeted antimicrobials among community-associated coliform bacteraemia associated
with the stewardship intervention (modelled interruption is date of primary care antimicrobial stewardship intervention plus 6 months).
Baseline resistance (rate
per 1,000 bacteraemia
episodes at start of time
series)a
Baseline trend (increase [+] or
decrease [−] per quarter of
rate per 1,000 bacteraemia
episodes)b
Step change at 6 months
postintervention (increase [+] or
decrease [−] in rate per 1,000
bacteraemia episodes)b
Change in trend at 6 months
postintervention (increase [+] or
decrease [−] in rate per quarter per 1,000
bacteraemia episodes)b
Fluoroquinolones 46.5 (13.2 to 79.8) +3.5 (0.7 to 6.3) −5.7 (−46.5 to 35.1) −4.4 (−7.8 to −1.0)
Cephalosporinsc 49.9 (4.1 to 95.6) +8.2 (3.3 to 13.1) −61.0 (−125.1 to 3.1) −7.0 (−12.6 to −1.5)
Co-amoxiclav 151.5 (87.1 to 215.8) +4.6 (−1.0 to 10.3) −13.5 (−98.8 to 71.8) −3.3 (−10.4 to 3.8)
aRate per 1,000 community-associated coliform bacteraemia episodes resistant to each antimicrobial.
bAnalysis prespecified an expected delay of 6 months between the stewardship intervention at the start of the second quarter of 2009 and any change in resistance. The
modelled interruption is therefore the start of the fourth quarter of 2009.
cA lag 4 term was included for cephalosporins to account for autocorrelation.
Abbreviations: AMR, antimicrobial resistance.
https://doi.org/10.1371/journal.pmed.1002825.t004
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Equivalent absolute reductions were −95.0 (−157.4 to −42.4) and −153.1 (−255.7 to −77.0)
resistant bacteraemia episodes per 1,000 per quarter by 1.5 and 3.5 years postintervention,
respectively (Table 5). The overall effect was that a rising trend essentially flattened. Differ-
ences between observed and predicted co-amoxiclav resistance were in the direction of a
reduction, consistent with flattening of a previously rising trend, but did not reach statistical
significance.
In the first post hoc sensitivity analyses comparing simple linear models of resistance out-
comes over time to the primary models, including an interruption at 6 months after the stew-
ardship intervention, AIC values indicated equivalent model fit (i.e., difference in AIC < 4) for
all three antimicrobials (S5 Table). However, testing the specific hypothesis that the interven-
tion was associated with changes in resistance requires fitting of an interruption, and model fit
was no worse, supporting the primary analysis as reasonable, although interpretation should
be cautious.
In the second post hoc sensitivity analyses comparing segmented regression resistance
models that exclude 2005 data to the primary segmented regression resistance models (model
outputs in S6 Table), the sensitivity analyses estimated relative changes at 1.5 and 3.5 years
postintervention that for fluoroquinolones were larger but had wider 95% CI, for cephalospo-
rins were slightly smaller with wider 95% CI, and for co-amoxiclav were slightly smaller with
wider 95% CI and remained nonsignificant (S7 Table). These are in accordance with interpre-
tation of the primary analyses, that the overall pattern is of reductions in resistance but the
magnitude of the changes is modest compared to those for changes in prescribing, and not all
changes are statistically significant. Again, this emphasises that interpretation of the resistance
models should be cautious.
Discussion
Summary of main findings
In this population-based study in Scotland, UK, large reductions in community prescribing of
broad-spectrum antimicrobials following an antimicrobial stewardship intervention were
associated with reductions in resistance among people admitted to hospital with community-
associated coliform bacteraemia. Reductions in resistance from those predicted by prior trends
were statistically significant by 1.5 years for cephalosporins (where rising rates flattened) and
by 3.5 years after the stewardship intervention for fluoroquinolones (where rising rates were
reversed). The changes in co-amoxiclav resistance were in the direction of flattening a rising
trend, although they were not statistically significant. By 3.5 years after the stewardship inter-
vention, the absolute changes were a reduction of 63.5 isolates resistant to fluoroquinolones
per 1,000 bacteraemia episodes, a reduction of 153.1 per 1,000 bacteraemia episodes resistant
Table 5. Estimated absolute and relative changes, compared to levels predicted by prior trends, in resistance among community-associated coliform bacteraemia at
1.5 and 3.5 years after primary care antimicrobial stewardship intervention (modelled interruption is date of primary care antimicrobial stewardship intervention
plus 6 months).
Absolute change at 1.5 years
postintervention compared to
predicted (rate with resistant
growth per 1,000 coliform
bacteraemia episodes)
Absolute change at 3.5 years
postintervention compared to
predicted (rate with resistant
growth per 1,000 coliform
bacteraemia episodes)
Relative change at 1.5 years
postintervention compared to
predicted (rate with resistant
growth per 1,000 coliform
bacteraemia episodes)
Relative change at 3.5 years
postintervention compared to
predicted (rate with resistant
growth per 1,000 coliform
bacteraemia episodes)
Fluoroquinolones −27.2 (−68.8 to 7.9) −63.5 (−131.8 to −12.8) −17.2% (−38.4 to 0.04) −34.7% (−52.3 to −10.6)
Cephalosporins −95.0 (−157.4 to −42.4) −153.1 (−255.7 to −77.0) −38.2% (−56.1 to −18.8) −48.3% (−62.7 to −32.3)
Co-amoxiclav −34.8 (−121.8 to 38.5) −63.6 (−206.4 to 42.4) −11.3% (−35.9 to 18.6) −17.8% (−47.1 to 20.8)
https://doi.org/10.1371/journal.pmed.1002825.t005
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to cephalosporins, and a nonsignificant reduction of 63.6 per 1,000 resistant to co-amoxiclav.
Multidrug resistance was rare.
Strengths of the study
A key strength of this study is the availability of longitudinal data in a complete geographical
population, allowing examination of long-term associations between a stewardship interven-
tion and both targeted broad-spectrum antimicrobial prescribing and resistance to targeted
broad-spectrum antimicrobials in serious community-associated infections. Further strengths
include that the data analysed are all captured as part of routine care, meaning the likelihood
of missing data is very low, and that Tayside has a very stable population, meaning observed
changes are unlikely to reflect changes in the population at risk. In addition, there were no sig-
nificant changes to the organisation of healthcare in Tayside over the study period, with the
same two acute hospitals serving the whole population. We know that total antimicrobial pre-
scribing in primary care did not change in association with the intervention [23,32], so it is
unlikely that changes in general practitioner consultation rates or patient demand for antimi-
crobials influenced the findings. In addition, health-seeking behaviour is less likely to influence
bacteraemia rates than positive community urine culture rates and cannot explain changes in
resistance rates.
The interrupted time series analysis (ITSA) used is a robust design for evaluation of real-
world interventions that cannot be randomised [33,34], and there were adequate time points
before and after the intervention in our data series. In comparison with uncontrolled before–
after (UBA) studies, which compare mean rates or proportions before and after an interven-
tion, ITSA accounts for pre- and postintervention trends and changes in trend at the time of
intervention. This is important for estimating intervention effects; for example, if the rate of
the outcome of interest increases before an intervention and then decreases after (as happens
with fluoroquinolone resistance in this analysis), then a UBA study may find that the mean
outcome before and after does not change because time trends are ignored. Similarly, if the
outcome was increasing preintervention and continued to increase at the same rate postinter-
vention, a UBA study would erroneously report an increase associated with the intervention.
Consistent with these limitations, UBA studies are not considered robust enough by the
Cochrane Effective Practice and Organisation of Care (EPOC) Group to be included in sys-
tematic reviews, whereas ITSAs are eligible for inclusion [35].
The focus on community-associated bacteraemia is a further strength that minimises con-
founding from unmeasured exposure to antimicrobials in hospital. The data analysed are from
one area of Scotland, but Tayside is representative (approximately 10%) of the wider Scottish
population in terms of sociodemographic characteristics and not dissimilar to other regions, at
least across the UK. There is no biological reason that an intervention elsewhere that is associ-
ated with similarly large changes in prescribing would not have similar associated changes in
resistance, so these findings are likely to be widely generalisable.
Limitations of the study
One weakness of the analysis is that observational studies can only examine and report associa-
tion, rather than causation, and it is impossible to exclude residual confounding, which, in the
case of ITSA, includes not knowing what the postintervention trends in the outcomes would
have been if the intervention had not occurred. Including a control group would have
strengthened the analysis, but there was no suitable control group because this intervention
was implemented across the entire health board, and all other Scottish health boards imple-
mented prescribing interventions of various kinds at around the same time in response to a
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national C. difficile infection outbreak. More specific to ITSA and to this data series, a weak-
ness is the relatively low number of bacteraemia episodes per time point (median 49.5 [IQR
37.7 to 59.2]), which increases variability between time points and reduces the power to detect
a true change. ITSA may also be at risk of bias if there are other major interventions in the
time period examined. There were no other major changes to community prescribing or infec-
tion control policies, but there was a parallel change in the NHS Tayside hospital prescribing
policy implemented at the end of 2008. The hospital policy included removing the same tar-
geted antimicrobials/classes (as the primary care policy) from first-line indicated therapy for
almost all infections. The only remaining first-line therapeutic indications in the hospital pol-
icy for targeted antimicrobials were fluoroquinolones for prostatitis, ceftriaxone for bacterial
meningitis (which are both uncommon), and co-amoxiclav for severe community-acquired
pneumonia (which is relatively common). It is possible that these changes had some effect on
resistance among coliforms circulating in the community, even though patients with a recent
hospital admission were excluded from the analysis. This is more likely for co-amoxiclav,
given that its use remained higher in hospital after the policy change, and may partly explain
the lack of significant reduction in co-amoxiclav resistance observed. The size and temporal
relationship of the changes we observed in prescribing are consistent with these being attribut-
able to the intervention. Given the smaller changes in resistance observed and the findings of
the sensitivity analyses, we are more cautious in our interpretation of the observed changes in
resistance, which reinforces the conclusion that large changes in community prescribing are
associated with more modest changes in resistance at best.
Comparison with the literature
Most antimicrobial prescribing is in the community, but the evidence base for antimicrobial
stewardship in the community [20] is weaker than in the hospital [18], and few studies have
robustly examined associations between community antimicrobial stewardship programs and
resistance. A pilot study aiming to prospectively recruit patients admitted to hospital with uri-
nary tract infection found an association between prior antimicrobial exposure and trimetho-
prim resistance in the index urine sample (crude odds ratio 3.58, 95% CI 1.18 to 10.9). The
findings were limited by the small sample size, and the authors concluded that a study using
routine data was required [32].
Gram-positive resistance has been shown to reduce in response to community-based stew-
ardship. For example, pneumococcal macrolide resistance in Finland fell from 19.0% to 8.6%
over 5 years following>40% reductions in macrolide use in the 1990s [21], and falling penicil-
lin use in Iceland was associated with 25% reductions in pneumococcal penicillin resistance
over 5 years [36]. Reported associations between community antimicrobial use and gram-neg-
ative resistance are less consistent. A 25% reduction in ciprofloxacin use in Israel lasting 7
months was associated with a reported reduction in fluoroquinolone resistance in urinary E.
coli isolates from 12% to 9% [37]. In contrast, an 86% reduction in trimethoprim use in Swe-
den over 24 months was not associated with any change in resistance in urinary isolates [38],
and sulphonamide resistance in the UK continued to rise in the 1990s despite the virtual end-
ing of sulphonamide use [39].
The inconsistent relationship between antimicrobial stewardship and subsequent resistance
observed in this study and others is likely related to the multiple mechanisms by which resis-
tance arises and persists. Antimicrobial prescribing leads to selection pressures that increase
resistance, but reducing antimicrobial use and therefore selection pressure will only rapidly
reverse resistance if there is a significant associated fitness cost to maintaining it [40–42]. The
cell wall structure in gram-positive bacteria results in higher fitness costs of resistance,
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consistent with observed reversibility of resistance after reductions in prescribing [21,36,43].
Fluoroquinolone resistance among E. coli has well-described associated fitness costs, but some
resistance mutations confer little or no cost to bacterial fitness, and certain resistance traits
may even be beneficial [42,43]. In addition, selection of resistance to a particular antimicrobial
may occur in the absence of exposure to that particular antimicrobial because of mutations for
resistance coexisting on the same plasmid and so being selected by other antimicrobial use
[42,43]. Changes in resistance in response to stewardship interventions would therefore be
predicted to have somewhat variable effects.
Implications of the findings
The findings are consistent with primary care antimicrobial stewardship targeting broad-spec-
trum antimicrobial prescribing being associated with worthwhile but delayed changes in resis-
tance in coliform bacteraemia, a serious infection. However, this is not the only potential
approach to containing resistance, and it may have limited impact if there is substitution with
other antimicrobials because of the risk of developing cross-resistance such as that mediated
by plasmids. Alternatives include reducing total antimicrobial prescribing and short-term
cycling. Reducing total antimicrobial prescribing is increasingly the strategy of choice in pri-
mary care [44], but this is complicated because of the risk of harm from undertreating high-
risk groups, including the elderly, if the treatment threshold is high [45]. It will therefore be
very important to collect balancing measures relating to infection outcomes in evaluating stew-
ardship that reduces total antimicrobial use [46]. Planned, short-term cycling of recommended
antimicrobials is an alternative strategy that aims to avoid sustained selection pressure of any
individual antimicrobial to limit the development of resistance. There is some evidence of
effectiveness of this approach in the controlled environment of intensive care units, although
reported associated changes in resistance are mixed in this context [47]. Short-term cycling is
limited by the small number of antimicrobials available for any indication, and its value in pri-
mary care remains to be established. Whatever strategy is chosen, the key problem remains
avoiding antimicrobial prescribing when it is not necessary, and judicious use of new antimi-
crobials is key to reducing or containing resistance. Optimising these approaches will require
improved clinical decision support and/or diagnostics at the point of care that overcome logis-
tical, financial, and behavioural barriers to their implementation [48].
Further research is needed to better understand broader mechanisms of changes in resis-
tance in response to antimicrobial stewardship interventions, including bacterial genomic
studies in combination with population data. ITSA is an appropriate method for evaluating
healthcare interventions that cannot be randomised, but the widespread application of ITSA
in a timely manner requires more responsive surveillance systems that use continuous moni-
toring of routine data.
Conclusion
The known mechanisms involved in gram-negative resistance are consistent with our findings
that very large (>60%) reductions in community antimicrobial use can help contain resistance
in coliform bacteraemia in this context but may not lower it from established rates. Notably,
the associated reduction in resistance was delayed, and rising resistance only truly reversed for
fluoroquinolones. Minimising broad-spectrum antimicrobial use in the community is clearly
of value in containing resistance in specific serious infections, but further research is required
to examine the impact on resistance more generally and other outcomes of community stew-
ardship interventions aiming to achieve large reductions in total antimicrobial use. The
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findings also emphasise the critical importance of careful use of new antibiotics to minimise
the initial development of resistance.
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